NASDAQ · Financial Statements
Aerpio Pharmaceuticals, Inc. (ARPO) Financial Statements
$2.20
NASDAQ: ARPO
Market Cap $53.67M
Overview Financials Dividend
Aerpio Pharmaceuticals, Inc. most recently reported annual revenue of $7.0M, a net loss of $21.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2020 2021 2022 2024 2025
Revenue $1.0M $4.0M $6.0M $26.0M $7.0M Operating Profit $-22.0M $-24.0M $-37.0M $-67.0M $-114.0M Net Profit $-22.0M $-23.0M $-37.0M $-64.0M $-21.0M EPS $-1.35 $-0.96 $-1.08 $-2.36 $-0.33 Op Margin -2623.0% -532.5% -670.8% -259.6% -1601.1%
Balance Sheet (USD)
Metric 2020 2021 2022 2024 2025
Total Assets $40.0M $70.0M $96.0M $70.0M $151.0M Total Liabilities $21.0M $44.0M $60.0M $18.0M $15.0M Cash $10.0M $10.0M $15.0M $29.0M $38.0M Borrowings $0 $0 $0 $1.0M $0
Cash Flow (USD)
Metric 2020 2021 2022 2024 2025
Operating Cash Flow $-18.0M $-24.0M $-32.0M $-60.0M $-97.0M Investing Cash Flow $-2.0M $-3.0M $-4.0M $24.0M $11.0M Financing Cash Flow $23.0M $26.0M $44.0M $0 $94.0M Net Cash Flow $4.0M $1.0M $9.0M $-34.0M $9.0M Free Cash Flow $-19.0M $-25.0M $-35.0M $-61.0M $-98.0M
Valuation & Return Ratios
Metric Value PEG Ratio -0.01 EV / EBITDA -0.16 FCF Yield -18.25% Quick Ratio 11.36 Interest Coverage — Return 1Y — Return 3Y — Return 5Y —
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer .